Rationale for cannabis-based interventions in the opioid overdose crisis.

 Biomed Central

“North America is currently in the grips of a crisis rooted in the use of licit and illicit opioid-based analgesics. Drug overdose is the leading cause of accidental death in Canada and the US, and the growing toll of opioid-related morbidity and mortality requires a diversity of novel therapeutic and harm reduction-based interventions.

Research suggests that increasing adult access to both medical and recreational cannabis has significant positive impacts on public health and safety as a result of substitution effect. Observational and epidemiological studies have found that medical cannabis programs are associated with a reduction in the use of opioids and associated morbidity and mortality.

The growing body of research supporting the medical use of cannabis as an adjunct or substitute for opioids creates an evidence-based rationale for governments, health care providers, and academic researchers to consider the implementation and assessment of cannabis-based interventions in the opioid crisis.”

https://www.ncbi.nlm.nih.gov/pubmed/28821296

Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions

“Legal access to cannabis may reduce the use of multiple classes of dangerous prescription medications in certain patient populations.”

http://en.ahau.findplus.cn/?h=articles&db=edselp&an=S1525861017304292

“Medical Cannabis and Reduced Prescription Use. 71% of medical cannabis program enrollees either ceased or reduced their use of scheduled prescriptions within 6 months of enrolling. The findings of this study indicate that once a patient enrolls in the medical cannabis program there is an increased likelihood that the patient will decrease their usage of scheduled medications. These medications include many drugs of abuse such as opiates, benzodiazepines, and sleeping medications.” http://markets.businessinsider.com/news/stocks/Medical-Cannabis-and-Reduced-Prescription-Use-1001600526

“Medical Cannabis and Reduced Prescription Use. Breakthrough Study Indicates Strong Association Between Medical Cannabis and Reduced Prescription Use.”  http://www.prnewswire.com/news-releases/medical-cannabis-and-reduced-prescription-use-300506774.html

“Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions. Legal access to cannabis may reduce the use of multiple classes of dangerous prescription medications in certain patient populations.”  https://www.ncbi.nlm.nih.gov/pubmed/28899660

“Legal access to cannabis may reduce the use of multiple classes of dangerous prescription medications in certain patient populations.” http://www.jamda.com/article/S1525-8610(17)30429-2/fulltext

The effects of cannabinoid receptors activation and glucocorticoid receptors deactivation in the amygdala and hippocampus on the consolidation of a traumatic event.

Cover image

“Ample evidence demonstrates that fear learning contributes significantly to many anxiety pathologies including post-traumatic stress disorder (PTSD). The endocannabinoid (eCB) system may offer therapeutic benefits for PTSD and it is a modulator of the hypothalamic pituitary adrenal (HPA) axis.

Here we compared the separated and combined effects of blocking glucocorticoid receptors (GRs) using the GR antagonist RU486 and enhancing CB1r signaling using the CB1/2 receptor agonist WIN55,212-2 in the CA1 and basolateral amygdala (BLA) on the consolidation of traumatic memory. Traumatic memory was formed by exposure to a severe footshock in an inhibitory avoidance apparatus followed by exposure to trauma reminders. Intra-BLA RU486 (10 ng/side) and WIN55,212-2 (5 μg/side) administered immediately after shock exposure dampened the consolidation of the memory about the traumatic event and attenuated the increase in acoustic startle response in rats exposed to shock and reminders. In the CA1, WIN55,212-2 impaired consolidation and attenuated the increase in acoustic startle response whereas RU486 had no effect. The effects of WIN55,212-2 were found to be mediated by CB1 receptors, but not by GRs. Moreover, post-shock systemic WIN55,212-2 (0.5 mg/kg) administration prevented the increase in GRs and CB1 receptor levels in the CA1 and BLA in rats exposed to shock and reminders.

The findings suggest that the BLA is a locus of action of cannabinoids and glucocorticoids in modulating consolidation of traumatic memory in a rat model of PTSD. Also, the findings highlight novel targets for the treatment of emotional disorders and PTSD in particular.”

https://www.ncbi.nlm.nih.gov/pubmed/28818702

http://www.sciencedirect.com/science/article/pii/S1074742717301284

Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels.

“Cannabidiol (CBD), the main nonpsychotomimetic compound from Cannabis sativa, inhibits experimental seizures in animal models and alleviates certain types of intractable epilepsies in patients.

Here we tested the hypothesis that CBD anticonvulsant mechanisms are prevented by cannabinoid (CB1 and CB2) and vanilloid (TRPV1) receptor blockers. We also investigated its effects on electroencephalographic (EEG) activity and hippocampal cytokines in the pentylenetetrazole (PTZ) model.

Pretreatment with CBD (60mg/kg) attenuated seizures induced by intraperitoneal, subcutaneous, and intravenous PTZ administration in mice. The effects were reversed by CB1, CB2, and TRPV1 selective antagonists (AM251, AM630, and SB366791, respectively). Additionally, CBD delayed seizure sensitization resulting from repeated PTZ administration (kindling). This cannabinoid also prevented PTZ-induced EEG activity and interleukin-6 increase in prefrontal cortex.

In conclusion, the robust anticonvulsant effects of CBD may result from multiple pharmacological mechanisms, including facilitation of endocannabinoid signaling and TRPV1 mechanisms. These findings advance our understanding on CBD inhibition of seizures, EEG activity, and cytokine actions, with potential implications for the development of new treatments for certain epileptic syndromes.”

https://www.ncbi.nlm.nih.gov/pubmed/28821005

http://www.epilepsybehavior.com/article/S1525-5050(17)30322-0/fulltext

Topical Medical Cannabis (TMC): A new treatment for wound pain-Three cases of Pyoderma Gangrenosum.

Cover image volume 54, Issue 2

“Pain associated with integumentary wounds is highly prevalent yet it remains an area of significant unmet need within healthcare. Currently, systemically administered opioids are the mainstay of treatment. However, recent publications are casting opioids in a negative light given their high side effect profile, inhibition of wound healing, and association with accidental overdose, incidents that are frequently fatal. Thus, novel analgesic strategies for wound-related pain need to be investigated.

The ideal methods of pain relief for wound patients are modalities that are topical, lack systemic side effects, non-invasive, self-administered, and display rapid onset of analgesia.

Extracts derived from the cannabis plant have been applied to wounds for thousands of years. The discovery of the human endocannabinoid system and its dominant presence throughout the integumentary system provides a valid and logical scientific platform to consider the use of topical cannabinoids for wounds.

We are reporting a prospective case series of 3 patients with Pyoderma Gangrenosum (PG) that were treated with Topical Medical Cannabis (TMC) compounded in non-genetically modified organic sunflower oil.

Clinically significant analgesia that was associated with reduced opioid utilization was noted in all 3 cases. TMC has the potential to improve pain management in patients suffering from wounds of all classes.”

https://www.ncbi.nlm.nih.gov/pubmed/28818631

http://www.jpsmjournal.com/article/S0885-3924(17)30351-2/fulltext

How Does Marijuana Effect Outcomes After Trauma in ICU Patients? A Propensity Matched Analysis

logo

“Unlike several studies that focus on the effects of marijuana on the outcomes of diseases, our aim was to assess the relationship between a positive toxicology screen for marijuana and mortality in such patients.

A positive marijuana screen is associated with decreased mortality in adult trauma patients admitted to the ICU.

This association warrants further investigation of the possible physiological effects of marijuana in trauma patients.”

https://insights.ovid.com/pubmed?pmid=28787375

Smoking Marijuana Can Reduce Risk Of Stroke, Study Finds.

Image result for university texas dallas
“Smoking marijuana can reduce the risk of a stroke to a large extent, a new study has found. In the states where marijuana use is legal, strains of the drug are prescribed to cure chronic pain, anxiety, and epilepsy. A new study conducted by the University of Texas at Dallas has found cannabis can improve a person’s health by enhancing the blood and oxygen flow, thus reducing the risk of blood clots and the possibility of a stroke.” http://www.ibtimes.com/smoking-marijuana-can-reduce-risk-stroke-study-finds-2579489
“Residual Effects of THC via Novel Measures of Brain Perfusion and Metabolism in a Large Group of Chronic Cannabis Users” https://www.nature.com/npp/journal/vaop/ncurrent/full/npp201744a.html
“Could cannabis PROTECT you from a stroke? People who smoke marijuana every day have better blood flow and oxygen to the brain, controversial study claims. A study by the University of Texas at Dallas has found the drug can improve oxygen and blood flow to the brain, reducing the risk of clots that cause a brain attack. In fact, the research team found chronic cannabis users have the most efficient brain blood flow of all, suggesting their stroke risk is lowest.” http://www.dailymail.co.uk/health/article-4797444/Cannabis-PROTECTS-stroke-study-claims.html

GPR55 – a putative “type 3” cannabinoid receptor in inflammation.

“G protein-coupled receptor 55 (GPR55) shares numerous cannabinoid ligands with CB1 and CB2 receptors despite low homology with those classical cannabinoid receptors. The pharmacology of GPR55 is not yet fully elucidated; however, GPR55 utilizes a different signaling system and downstream cascade associated with the receptor. Therefore, GPR55 has emerged as a putative “type 3” cannabinoid receptor, establishing a novel class of cannabinoid receptor. Furthermore, the recent evidence of GPR55-CB1 and GPR55-CB2 heteromerization along with its broad distribution from central nervous system to peripheries suggests the importance of GPR55 in various cellular processes and pathologies and as a potential therapeutic target in inflammation.”

GPR55 G protein-coupled receptor 55 [ Homo sapiens (human) ]

Image result for GPR55 cannabinoid receptor

“This gene belongs to the G-protein-coupled receptor superfamily. The encoded integral membrane protein is a likely cannabinoid receptor. It may be involved in several physiological and pathological processes by activating a variety of signal transduction pathways. ” https://www.ncbi.nlm.nih.gov/gene/9290

“The orphan receptor GPR55 is a novel cannabinoid receptor”  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095107/

The orphan receptor GPR55 is a novel cannabinoid receptor

Logo of brjpharm

“Preparations of Cannabis sativa have been used for medicinal and recreational purposes for at least 4000 years and extracts of C. sativa contain over 60 different pharmacologically active components the most prominent being Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol

Ligands such as cannabidiol and abnormal cannabidiol which exhibit no CB1or CB2 activity and are believed to function at a novel cannabinoid receptor, also showed activity at GPR55.

These data suggest that GPR55 is a novel cannabinoid receptor, and its ligand profile with respect to CB1and CB2 described here will permit delineation of its physiological function(s).”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095107/